Answers are grounded in this paper and cite their sources.
Non-hormonal contraceptive reduces trophoblast cell proliferation in rat models, indicating potential for safer women's healthcare.
Unintended pregnancy remains a significant concern in women's healthcare. Although current short-term contraceptive methods, particularly hormonal approaches, are effective in preventing unintended pregnancy, their potential long-term adverse effects necessitate the development of safer alternatives. A nanostrategy that interrupts early pregnancy by inhibiting embryonic trophoblast cell proliferation presents a promising non-hormonal approach with minimal adverse effects on female reproductive system. In this study, we further advanced this strategy by designing a highly effective, low-dose contraceptive using vitamin B13 copper metal-organic framework (VB13 Cu-MOF) as the active agent. VB13 Cu-MOF exhibited rapid dissolution in aqueous environments with a sustained and low Cu²⁺ release rate, facilitating preferential uptake by embryonic trophoblast cells due to their tumor-like characteristics. Upon contact with cells in the in vitro cellular model, the released Cu²⁺ was transported into cells via proteins on cell membrane in two pathways, direct Cu²⁺ intracellular transport, and Cu²⁺ reduction to Cu⁺ and Cu+ intracellular transport. Both Cu²⁺ and Cu⁺ in cells triggered parallel Fenton-like reactions, resulting in excessive reactive oxygen species generation, mitochondrial damage, apoptosis, and ferroptosis. RNA-seq analysis identified the key biological processes and the associated genes involved in these interactions. In vivo experiments in rat models demonstrated contraceptive efficacy using VB13 Cu-MOF at an ultra-low dose (65 μg/mL) and its hydrogel formulation, without inducing adverse effects on serum copper levels, estrogen concentrations, inflammatory markers, or organ morphology. These findings establish VB13 Cu-MOF as a promising non-hormonal contraceptive with strong potential to prevent unintended pregnancies while minimizing risks to women's health. STATEMENT OF SIGNIFICANCE: Vitamin 13 copper metal-organic Framework (VB13 Cu-MOF) was designed and developed as a bioactive material for female non-hormonal contraceptives. As a new source of copper ions, VB13 Cu-MOF demonstrated a controlled release of copper ions, effectively targeting and inducing trophoblast cell death to achieve high contraceptive efficacy in a rat model at low dosage, without causing adverse effects in vitro or in vivo. Moreover, VB13 can increase the histocompatibility of Cu-MOF to normal cells. VB13 Cu-MOF was employed to validate a novel contraceptive mechanism targeting trophoblast cells to interrupt the pregnancy process 5-8 days after mating. Significantly, this demonstrates its potential as a promising non-hormonal contraceptive for clinical use, contributing to enhanced women's healthcare.
No takes yet. Share an insight, caveat, or question.
Su et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: